Latest News and Press Releases

aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal

aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor for efzofitimod program in interstitial lung disease (ILD).

Second Fast Track designation for efzofitimod clinical program. Efzofitimod previously received FDA orphan drug designation for systemic sclerosis (SSc). SAN DIEGO, Sept. 13, 2022 (GLOBE NEWSWIRE)...

CARY, NC , Aug. 30, 2022 (GLOBE NEWSWIRE) -- APIE Therapeutics (APIE Tx), a preclinical pharmaceutical company pioneering novel and proprietary drugs to activate the apelin receptor (APJ), presented...

Las Vegas, USA, June 22, 2022 (GLOBE NEWSWIRE) -- Interstitial Lung Disease Clinical Trial Pipeline Insights | DelveInsight Interstitial lung disease Pipeline involves 120+ key companies...

GLENVIEW, Ill., May 17, 2022 (GLOBE NEWSWIRE) -- The American College of Chest Physicians (CHEST) and Three Lakes Foundation are announcing a steering committee of experts in the fields of pulmonary...

SEATTLE, Dec. 27, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global interstitial lung disease market is estimated to be valued at US$ 1578.9 million in 2021 and is expected...

SAN DIEGO , Aug. 14, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...